Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study
Table 2
Crude and adjusted hazard ratio for Urotract Cancer in the follow-up period.
All
Female
Male
IC
Non-IC
IC
Non-IC
IC
Non-IC
N =10192
N =30576
N =8233
N =24699
N =1959
N =5877
Bladder Cancer (n)
37(0.36)
19(0.06)
20(0.24)
14(0.06)
17(0.87)
5(0.09)
Median follow-up time, year
6.04
6.02
6.03
5.99
6.10
6.17
Crude HR (95%CI)
5.84(3.36-10.15)
1.00
4.27(2.16-8.45)
1.00
10.30(3.80-27.93)
1.00
P-value
<0.0001
<.0001
<0.0001
Adjusted HR1 (95%CI)
5.44(3.10-9.54)
1.00
3.52(1.75-7.08)
1.00
10.57(3.87-28.87)
1.00
P-value
<0.0001
0.0004
<0.0001
Adjusted HR2 (95%CI)
5.66(3.21-9.99)
1.00
3.57(1.77-7.20)
1.00
12.00(4.31-33.45)
1.00
P-value
<0.0001
0.0004
<0.0001
Upper urinary tract cancer (n)
22(0.22)
30(0.10)
17(0.21)
22(0.09)
5(0.26)
8(0.14)
Median follow-up time, year
6.05
6.02
6.03
5.99
6.12
6.17
Crude HR (95%CI)
2.19(1.27-3.80)
1.00
2.31(1.22-4.34)
1.00
1.89(0.62-5.78)
1.00
P-value
0.0051
0.0097
0.2640
Adjusted HR1 (95%CI)
1.97(1.13-3.45)
1.00
2.16(1.13-4.13)
1.00
1.46(0.47-4.54)
1.00
P-value
0.0174
0.0199
0.5143
Adjusted HR2 (95%CI)
2.01(1.14-3.55)
1.00
2.13(1.11-4.10)
1.00
1.59(0.50-5.11)
1.00
P-value
0.0158
0.0239
0.4331
Prostate Cancer (n)
11(0.56)
25(0.43)
Median follow-up time, year
6.11
6.16
Crude HR (95%CI)
1.33(0.66-2.71)
1.00
P-value
0.4274
Adjusted HR1 (95%CI)
1.42(0.69-2.90)
1.00
P-value
0.3400
Adjusted HR2 (95%CI)
1.56(0.74-3.30)
1.00
P-value
0.2434
This table is adjusted by age, gender, DM, HTN, renal disease, CAD, hyperlipidemia, geographic region, and income; CCI score was added in adjusted HR2.
